RECRUITING Phase 2 ClinicalTrials.gov

ROMANCE: "Irinotecan Plus Cetuximab Rechallenge Versus Trifluridine/Tipiracil Plus Bevacizumab in Molecularly Selected Metastatic Colorectal Cancer"

Sponsor: Gruppo Oncologico Italia Meridionale • ClinicalTrials.gov ID: NCT07381764

Registry updated: 2026-09-11

Recruiting for Similar Conditions?

Sponsors are looking for patients like you. See if you qualify for compensated research studies.

Description

This study is a phase II, open-label, multicenter clinical trial designed to evaluate two different treatment options for patients with metastatic colorectal cancer whose disease has progressed after standard therapies. The study compares a rechallenge treatment using irinotecan plus cetuximab with the current standard of care, trifluridine/tipiracil plus bevacizumab, as third-line therapy. Patients enrolled in the study are selected based on specific molecular characteristics of their cancer, identified through circulating tumor DNA analysis from a blood sample. The main purpose of the study is to determine whether the rechallenge with irinotecan and cetuximab leads to a higher tumor response rate compared with trifluridine/tipiracil plus bevacizumab. Secondary objectives include evaluating progression-free survival, overall survival, safety, and quality of life. Patients will be randomly assigned to one of the two treatment groups and will receive treatment until disease progression, unacceptable side effects, or withdrawal of consent. Tumor response will be assessed using standard imaging techniques according to RECIST criteria.

Interventions

Erbitux (Cetuximab) (Drug)
This is an anti-EGFR monoclonal antibody administered in combination with chemotherapy. The dose is 500 mg/m2 over 120 minutes
Bevacizumab (Drug)
This is an anti-VEGF monoclonal antibody used as an active comparator in the control arm of the study. The dose is 5 mg/Kg of body weight given once every 2 weeks.
Irinotecan (Drug)
Irinotecan is a cytotoxic chemotherapy agent administered intravenously in combination with cetuximab the dose is 180 mg/m2 over 90 minutes, once every 2 weeks.
Trifluridine/tipiracil (Drug)
Trifluridine/tipiracil is an oral antineoplastic combination administered in combination with bevacizumab as part of the control treatment arm. The dose is 5 mg/ m² twice daily on Days 1 to 5 and Days 8 to 12 on a cycle of 28 days.

Eligibility criteria

Inclusion Criteria: 1. Male or female aged ≥18 years 2. Eastern Cooperative Oncology Group Performance Status (ECOG-PS) ≤1 3. Diagnosis of histologically or cytologically confirmed colorectal cancer. 4. At least one measurable lesion according to RECIST1.1 5. KRAS/NRAS/BRAFV600E wt status of primary CRC or related metastasis (local laboratory assessment). 6. Progression to previous first-line anti-EGFR-containing therapy producing at least a partial response ≥ 6 months. 7. Received and progressed to an anti-EGFR and irinotecan free second-line treatment. 8. Have an anti-EGFR free interval of at least 4 months. 9. Refractory to previous 5-fluorouracil/capecitabine, irinotecan, oxaliplatin, bevacizumab. 10. RAS/BRAF/EGFR/PIK3CAex20/MAP2K1/MET WT and HER2 not amplified ctDNA at FoundationOne CDx test at baseline. 11. Life expectancy of at least 3 months. 12. Adequate hematological function defined by white blood cell (WBC) count ≥ 2.5 × 109/L with absolute neutrophil count (ANC) ≥ 1.5 × 109/L, lymphocyte count ≥ 0.5 × 109/L, platelet count ≥ 100 × 109/L, and hemoglobin ≥ 9 g/dL (may have been transfused). 13. Adequate hepatic function defined by a total bilirubin level ≤ 1.5 × the upper limit of normal (ULN) range and AST and alanine aminotransferase (ALT) levels ≤ 2.5 × ULN for all subjects or AST and ALT levels ≤ 5 x ULN (for subjects with documented metastatic disease to the liver). 14. Adequate renal function defined by an estimated creatinine clearance \> 30 mL/min according to the Cockcroft-Gault formula (or local institutional standard method). 15. No contraindication to the study drugs. 16. No prior treatment with trifluridine/tipiracil. 17. Women of childbearing potential\* must have a negative blood pregnancy test at thescreening visit. Subjects and their partners must be willing to avoid pregnancy during the trial. \*A woman is considered of childbearing potential (WOCBP), i.e. fertile, following menarche and until becoming post-menopausal unless permanently sterile. Permanent sterilisation methods include hysterectomy, bilateral salpingectomy and bilateral oophorectomy. 18. Women of childbearing potential, or male, must agree to use adequate contraception (e.g., abstinence, intrauterine device, oral contraceptive, or double-barrier method), during the study and until at least 6 months after last dose of study treatment administration, based on the judgment of the Investigator or a designated associate. 19. Will and ability to comply with the protocol. 20. Signed informed consent obtained before screening. Exclusion Criteria: 1. ECOG PS ≥2 2. Received more than 2 lines of treatment for metastatic disease. 3. Previous treatment with trifluridine/tipiracil 4. RAS/BRAF/EGFR/PIK3CAex20/MAP2K1/MET WT HER2 not amplified status at liquid biopsy analysis during screening. 5. Previous history of malignancy within the last 2 years will be excluded with the exception of localized basal and squamous cell carcinoma or cervical cancer in situ 6. Evidence of bleeding diathesis or coagulopathy. 7. Uncontrolled hypertension and prior history of hypertensive crisis or hypertensive encephalopathy. 8. Known severe hypersensitivity to investigational product or any component in its formulations, including known severe hypersensitivity reactions to monoclonal antibodies (NCI CTCAE v 5 Grade ≥ 3), any history of anaphylaxis, or uncontrolled asthma (that is, 3 or more features of partially controlled asthma). 9. Clinically significant cardiovascular disease, active inflammatory bowel disease, active autoimmune disease. 10. Diagnosis of interstitial pneumonitis or pulmonary fibrosis. 11. History of abdominal fistula, GI perforation, intra-abdominal abscess or active gastrointestinal bleeding within 6 months prior to the first study treatment. 12. Pregnant or lactating women. 13. Psychiatric or addictive disorders would preclude study participation. 14. Active uncontrolled infections or other clinically relevant concomitant illness contraindicating study treatments. 15. Withdrawal of the consent to take part to the study.

Conditions

Metastatic Colorectal Cancer (CRC)

Locations

Azienda Ospedaliero Universitaria "SS Antonio e Biagio e Cesare Arrigo" — Alessandria, Italy
A.O.U. Ospedali Riuniti — Ancona, Italy
Centro di Riferimento Oncologico (CRO), IRCCS — Aviano, Italy
A.O.R.N. "Sant'anna e San Sebastiano" — Caserta, Italy
Ospedale IRCCS 'Saverio de Bellis' — Castellana Grotte, Italy
A.R.N.A.S. Garibaldi - P.O. Garibaldi-Nesima — Catania, Italy
Azienda Ospedaliero-Universitaria Renato Dulbecco — Catanzaro, Italy
A.O.U. Careggi — Florence, Italy
Istituto Romagnolo per lo Studio dei Tumori 'Dino Amadori' — Meldola, Italy
ASST Grande Ospedale Metropolitano Niguarda — Milan, Italy
Fondazione IRCCS Istituto Nazionale Tumori — Milan, Italy
Istituto Europeo di Oncologia — Milan, Italy
Casa di Cura Villa Maria — Mirabella Eclano, Italy
AOU Policlinico di Modena — Modena, Italy
A.O.U. dell'Università degli studi della Campania "Luigi Vanvitelli" — Naples, Italy
Istituto Nazionale Tumori 'Fondazione G. Pascale' — Naples, Italy
Istituto Oncologico Veneto IRCCS — Padova, Italy
ARNAS Civico - Di Cristina-Benfratelli - P. O. 'Civico e Benfratelli' — Palermo, Italy
Casa di cura Macchiarella — Palermo, Italy
A.O.U. Pisana — Pisa, Italy
Fondazione Policlinico Universitario 'Agostino Gemelli' IRCCS — Roma, Italy
Fondazione IRCCS Ospedale Casa Sollievo della Sofferenza — San Giovanni Rotondo, Italy
A.O.U. Sassari — Sassari, Italy
Ospedale San Giuseppe Moscati — Statte, Italy
A.O. 'Pia Fondazione Cardinale G. Panico' — Tricase, Italy
ASST Sette Laghi-Ospedale di Circolo Fondazione Macchi — Varese, Italy

Partner with Nurenyx

Showcase your study to thousands of motivated patients matching your criteria.

Learn More

Official Source

Data sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

View Official Record

Accelerate Your Clinical Trial Recruitment